Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer
June 2, 2025 updated by: National Cancer Institute (NCI)
A Randomized Phase 1/2 Trial Evaluating the Addition of Tolinapant to Weekly Paclitaxel With or Without Bevacizumab in Patients With Recurrent Epithelial Ovarian Cancer
This phase I/II trial tests the safety, best dose and effectiveness of adding tolinapant (ASTX660) to paclitaxel with or without bevacizumab in treating patients with ovarian cancer that has come back after a period of improvement (recurrent).
Tolinapant may stop the growth of tumor cells by blocking proteins, such as XIAP and cIAP1, that promote the growth of tumor cells and increase resistance to chemotherapy.
Paclitaxel is in a class of medications called antimicrotubule agents.
It stops tumor cells from growing and dividing and may kill them.
Bevacizumab is in a class of medications called antiangiogenic agents.
It works by stopping the formation of blood vessels that bring oxygen and nutrients to the tumor.
This may slow the growth and spread of tumor cells.
Adding ASTX660 to paclitaxel with or without bevacizumab may be safe, tolerable and/or effective in treating patients with recurrent ovarian cancer.
Study Overview
Status
Withdrawn
Conditions
- Recurrent Ovarian High Grade Serous Adenocarcinoma
- Recurrent Platinum-Resistant Ovarian Carcinoma
- Recurrent Fallopian Tube Clear Cell Adenocarcinoma
- Recurrent Fallopian Tube Undifferentiated Carcinoma
- Recurrent Ovarian Clear Cell Adenocarcinoma
- Recurrent Ovarian Undifferentiated Carcinoma
- Recurrent Platinum-Resistant Fallopian Tube Carcinoma
- Recurrent Platinum-Resistant Primary Peritoneal Carcinoma
- Recurrent Primary Peritoneal Clear Cell Adenocarcinoma
- Recurrent Primary Peritoneal Undifferentiated Carcinoma
- Platinum-Refractory Fallopian Tube Carcinoma
- Platinum-Refractory Ovarian Carcinoma
- Platinum-Refractory Primary Peritoneal Carcinoma
- Recurrent Fallopian Tube High Grade Serous Adenocarcinoma
- Recurrent Ovarian Seromucinous Carcinoma
- Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma
- Recurrent Ovarian Carcinosarcoma
- Recurrent Fallopian Tube Adenocarcinoma
- Recurrent Fallopian Tube Carcinosarcoma
- Recurrent High Grade Endometrioid Adenocarcinoma
- Recurrent Ovarian Adenocarcinoma
- Recurrent Primary Peritoneal Adenocarcinoma
- Recurrent Primary Peritoneal Carcinosarcoma
Detailed Description
PRIMARY OBJECTIVES:
I. To assess the safety and tolerability of adding ASTX660 (tolinapant) to a regimen of weekly paclitaxel with bevacizumab. (Phase I) II. To determine the recommended phase 2 dose (RP2D) for the combination of ASTX660 (tolinapant) and weekly paclitaxel with bevacizumab. (Phase I) III. To assess the efficacy of adding ASTX660 (tolinapant) to weekly paclitaxel, with or without bevacizumab (investigator choice), as measured by progression free survival (PFS). (Phase II)
SECONDARY OBJECTIVES:
I. To assess the objective response rate (ORR) of the addition of ASTX660 (tolinapant) to weekly paclitaxel with or without bevacizumab as compared to weekly paclitaxel with or without bevacizumab.
II. To assess overall survival.
EXPLORATORY OBJECTIVE:
I. To explore whether lack of cIAP1 expression results in no benefit for the addition of ASTX660 (tolinapant) to weekly paclitaxel +/- bevacizumab.
OUTLINE: This is a phase I, dose escalation study of ASTX660 and paclitaxel with or without bevacizumab followed by a dose expansion study. The phase II study will follow completion of the phase I study.
PHASE I:
Patients receive paclitaxel intravenously (IV) on days 1, 8 and 15, bevacizumab IV on days 1 and 15, and ASTX660 orally (PO) on days 1-7 and 15-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, computed tomography (CT) and magnetic resonance imaging (MRI) throughout the study.
PHASE II: Patients are randomized to 1 of 2 arms.
ARM I (CONTROL): Patients receive paclitaxel IV on days 1, 8, and 15 of each cycle. Patients may also receive bevacizumab IV on days 1 and 15 of each cycle per provider. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, CT and MRI throughout the study.
ARM II (EXPERIMENTAL): Patients receive paclitaxel IV on days 1, 8, and 15 and ASTX660 PO on days 1-7 and 15-21 of each cycle. Patients may also receive bevacizumab IV on days 1 and 15 of each cycle per provider. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, CT and MRI throughout the study.
After completion of study treatment, patients are followed up every 3 months for 2 years then every 6 months for 3 years.
Study Type
Interventional
Phase
- Phase 2
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
Pathologically (histologically or cytologically) proven diagnosis of high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer. Required: submission of pathology report
Patients with the following histologic cell types are eligible:
- High grade serous
- Endometrioid, grade 3
- Clear cell
- Undifferentiated
- Mixed epithelial
- Carcinosarcoma
- Adenocarcinoma, not otherwise specified (NOS)
Patients must be considered to have platinum-resistant or platinum-refractory recurrent ovarian cancer to be enrolled in this trial
- Platinum-resistant disease is defined as progression within < 6 months from completion of platinum-based therapy. The date should be calculated from the last administered dose of platinum therapy
- Platinum-refractory disease is defined as progression within 30 days of completing the last dose of platinum during initial therapy. The date should be calculated from the last administered dose of platinum therapy
- Patients must have evaluable disease or measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be ≥ 10 mm when measured by CT or MRI. Lymph nodes must be ≥ 15 mm in short axis when measured by CT or MRI. Previously irradiated lesions can be considered as measurable disease only if progressive disease has been unequivocally documented at that site since radiation
- Patients with treated brain metastases are eligible if follow up brain imaging after central nervous system (CNS) directed therapy shows no evidence of progression
Patients must have received ≥ 1 platinum-based therapy and not more than 5 prior lines of therapies. Notes:
- Adjuvant/neoadjuvant therapy is counted as only 1 regimen in the absence of intervening progression.
- Maintenance therapy (e.g., bevacizumab, poly adenosine diphosphate-ribose polymerase [PARP] inhibitor will be considered part of the preceding line of therapy [i.e., not counted independently])
- Therapy changed due to toxicity in the absence of progression will be considered part of the same line (i.e., not counted independently)
- Hormonal therapy will not be counted as a separate line of therapy
- Age ≥ 18
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- Absolute neutrophil count (ANC) ≥ 1,500 cells/mm^3
- Platelets ≥ 100,000 cells/mm^3
- Hemoglobin ≥ 8 g/dl
- Creatinine ≤ institutional upper limit of normal (ULN), OR calculated creatinine clearance (CrCL) of ≥ 50 mL/min by the Cockcroft-Gault formula
- Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (patients with known Gilbert's disease who have bilirubin level ≤ 3 x ULN may be enrolled)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x institutional ULN
- Patients with a known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
- The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information
- No active infection requiring parental antibiotics
- No evidence of intra-abdominal abscess, abdominal/pelvic fistula, gastrointestinal perforation, gastrointestinal (GI) obstruction, and/or with drainage gastrostomy tube required. NOTE: required interval since last bowel obstruction: 30 day minimum for incomplete obstruction, resolved with conservative means; 6 months for fistula
Exclusion Criteria:
- Patients who have received prior weekly paclitaxel in a platinum-resistant setting
- Major surgical procedure within 28 days prior to registration, or anticipation of need for major surgical procedure during the study. Note: Placement of a vascular access device, thoracentesis, and/or paracentesis will not be considered major surgery
- Women who are pregnant or are unwilling to discontinue nursing
- Evidence of bleeding diathesis or clinically significant coagulopathy within the past 3 months. Patients are not excluded for past or current use of anticoagulation
- Uncontrolled hypertension (systolic blood pressure [SBP] > 150 and/or diastolic blood pressure [DBP] > 90)
- Patients currently taking and unwilling/unable to discontinue the use of drugs that are known to inhibit or induce P-glycoprotein (gp)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Phase I (paclitaxel, tolinapant, bevacizumab)
Patients receive paclitaxel IV on days 1, 8 and 15, bevacizumab IV on days 1 and 15, and ASTX660 PO on days 1-7 and 15-21 of each cycle.
Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Additionally, patients undergo blood sample collection, CT and MRI throughout the study.
|
Undergo MRI
Other Names:
Given IV
Other Names:
Undergo CT
Other Names:
Undergo blood sample collection
Other Names:
Given IV
Other Names:
Given PO
Other Names:
|
|
Active Comparator: Phase II, Arm I (paclitaxel, bevacizumab)
Patients receive paclitaxel IV on days 1, 8, and 15 of each cycle.
Patients may also receive bevacizumab IV on days 1 and 15 of each cycle per provider.
Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Additionally, patients undergo blood sample collection, CT and MRI throughout the study.
|
Undergo MRI
Other Names:
Given IV
Other Names:
Undergo CT
Other Names:
Undergo blood sample collection
Other Names:
Given IV
Other Names:
|
|
Experimental: Phase II, Arm II (paclitaxel, tolinapant, bevacizumab)
Patients receive paclitaxel IV on days 1, 8, and 15 and ASTX660 PO on days 1-7 and 15-21 of each cycle.
Patients may also receive bevacizumab IV on days 1 and 15 of each cycle per provider.
Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Additionally, patients undergo blood sample collection, CT and MRI throughout the study.
|
Undergo MRI
Other Names:
Given IV
Other Names:
Undergo CT
Other Names:
Undergo blood sample collection
Other Names:
Given IV
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of dose-limiting toxicity (Phase I)
Time Frame: At 28 days
|
Assessed using the Bayesian Optimal Interval design.
Toxicity will be graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0.
|
At 28 days
|
|
Progression free survival (PFS) (Phase II)
Time Frame: At randomization to progressive disease or death, assessed up to 5 years after completion of study treatment
|
The primary hypothesis test will be based on a logrank test, stratified on factors declared at randomization.
The PFS hazard ratio will be estimated by Cox regression, stratified by factors declared at randomization.
The treatment hazard ratio estimates and their 95% confidence intervals will be estimated using proportional hazards models specified to be consistent with the logrank tests.
|
At randomization to progressive disease or death, assessed up to 5 years after completion of study treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of adverse events (AEs)
Time Frame: Up to 30 days after last dose of study treatment
|
AEs will be defined as any untoward medical occurrence associated wtih the use of a drug in humans, whether or not considered drug related.
AEs will be graded using NCI CTCAE v5.0.
All AEs will be summarized.
|
Up to 30 days after last dose of study treatment
|
|
Overall survival (OS)
Time Frame: At randomization to death, assessed up to 5 years after completion of study treatment
|
OS will be defined as the time from randomization to death from any cause.
The OS treatment hypothesis will be based on a logrank test, stratified by the factors specified at randomization.
Comparisons of the OS distributions by treatment arm will be described using Kaplan-Meier methods.
Treatment hazard ratio estimates and their 95% confidence intervals will be estimated using a multivariable proportional hazards model specified with main effects for the randomization treatment assignment and stratified by the factors declared at randomization.
|
At randomization to death, assessed up to 5 years after completion of study treatment
|
|
Objective response rate (ORR)
Time Frame: At start of treatment to disease progression/recurrence, assessed up to 5 years after completion of treatment
|
ORR will be defined as the binomial proportion of evaluable patients with a best overall response of complete response (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors.
The ORR estimates by treatment arm will be supported by their 2-sided, 95% Wilson-Score confidence intervals.
The relative odds of response in the experimental arm will be estimated using a multivariable logistic regression model specified with main effects for the treatment groups and stratified by the stratification factors reported at baseline.
|
At start of treatment to disease progression/recurrence, assessed up to 5 years after completion of treatment
|
|
Duration of response (DOR)
Time Frame: At first response to progression or death, assessed up to 5 years after completion of study treatment
|
DOR will be defined as the time from first documentation of either PR or CR until disease progression or death, whichever is observed first.
Treatment group differences in response duration will be graphed using Kaplan-Meier methods and compared using logrank tests, stratified by the factors declared at randomization.
The relative hazards of progression or death in each group will be estimated using similarly stratified proportional hazards regression model specified with main effects for the treatment indicator.
|
At first response to progression or death, assessed up to 5 years after completion of study treatment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Lack of cIAP1 expression
Time Frame: Up to 5 years after completion of study treatment
|
Will evaluate whether lack of cIAP1 expression results in no benefit for the addition of ASTX660 to weekly paclitaxel.
The null hypothesis of no predictive effect of cIAP1 on clinical outcomes will be assessed using the type 3 score test for the interaction of the randomized treatment assignment and the patient-level cIAP1 histopathological-score classification (positive, reference negative).
The type 3 test result will be obtained from a multivariable Cox regression model model specified with main effects for the randomized treatment assignment and the cIAP1 classification (negative/positive), and the interaction term.
The model may be stratified by bevacizumab use.
Treatment hazard ratios and 95% confidence intervals will be estimated within the cIAP1 subgroups, and graphed in a forest plot to assess qualitative interactions.
|
Up to 5 years after completion of study treatment
|
|
ORR (Phase I/Ib)
Time Frame: Up to 5 years after completion of study treatment
|
ORR will be compared among patients enrolled in the phase I/Ib parts of the trial.
Treatment effect estimates of clinical benefit will be descriptive.
|
Up to 5 years after completion of study treatment
|
|
PFS (Phase I/Ib)
Time Frame: Up to 6 months after starting treatment
|
PFS will be compared among patients enrolled in the phase I/Ib parts of the trial.
Treatment effect estimates of clinical benefit will be descriptive.
Dose level effects on PFS will be described using Kaplan Meier methods.
Treatment effectiveness will be quantified using estimates for the proportion of patients who are alive without documented progression 6 months after starting treatment.
|
Up to 6 months after starting treatment
|
|
OS (Phase I/Ib)
Time Frame: Up to 6 months after starting treatment
|
OS will be compared among patients enrolled in the phase I/Ib parts of the trial.
Treatment effect estimates of clinical benefit will be descriptive.
Dose level effects on oS will be described using Kaplan Meier methods.
Treatment effectiveness will be quantified using estimates for the proportion of patients who are alive 6 months after starting treatment.
|
Up to 6 months after starting treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Kristen P Zeligs, NRG Oncology
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
October 31, 2025
Primary Completion (Estimated)
February 9, 2028
Study Completion (Estimated)
February 9, 2028
Study Registration Dates
First Submitted
April 30, 2024
First Submitted That Met QC Criteria
April 30, 2024
First Posted (Actual)
May 1, 2024
Study Record Updates
Last Update Posted (Actual)
June 3, 2025
Last Update Submitted That Met QC Criteria
June 2, 2025
Last Verified
June 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Endocrine System Diseases
- Pathologic Processes
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Disease Attributes
- Neoplasms by Histologic Type
- Genital Diseases, Female
- Endocrine Gland Neoplasms
- Neoplasms, Glandular and Epithelial
- Ovarian Diseases
- Adnexal Diseases
- Genital Neoplasms, Female
- Gonadal Disorders
- Uterine Neoplasms
- Sarcoma
- Neoplasms, Connective and Soft Tissue
- Cystadenocarcinoma
- Neoplasms, Cystic, Mucinous, and Serous
- Neoplasms, Complex and Mixed
- Endometrial Neoplasms
- Fallopian Tube Diseases
- Carcinoma, Ovarian Epithelial
- Recurrence
- Carcinoma
- Ovarian Neoplasms
- Adenocarcinoma
- Cystadenocarcinoma, Serous
- Carcinosarcoma
- Mixed Tumor, Mullerian
- Carcinoma, Endometrioid
- Adenocarcinoma, Clear Cell
- Fallopian Tube Neoplasms
- Antineoplastic Agents
- Immunologic Factors
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Bevacizumab
- Albumin-Bound Paclitaxel
- Antineoplastic Agents, Immunological
- Antibodies
- Immunoglobulins
- Antibodies, Monoclonal
- Paclitaxel
- Immunoglobulin G
- Endothelial Growth Factors
Other Study ID Numbers
- NCI-2024-03344 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- U10CA180868 (U.S. NIH Grant/Contract)
- NRG-GY034 (Other Identifier: CTEP)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
NCI is committed to sharing data in accordance with NIH policy.
For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Ovarian High Grade Serous Adenocarcinoma
-
National Cancer Institute (NCI)Not yet recruitingRecurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma | Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma | Recurrent Platinum-Sensitive Fallopian Tube Endometrioid... and other conditions
-
M.D. Anderson Cancer CenterActive, not recruitingRecurrent Primary Peritoneal High Grade Serous Adenocarcinoma | High Grade Ovarian Serous Adenocarcinoma | Recurrent High Grade Fallopian Tube Serous Adenocarcinoma | Recurrent High Grade Ovarian Serous Adenocarcinoma | High Grade Fallopian Tube Serous Adenocarcinoma | Peritoneal High Grade...United States
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingOvarian Seromucinous Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Fallopian Tube Mucinous Adenocarcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent... and other conditionsUnited States, Puerto Rico
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Fallopian Tube Transitional Cell Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Clear... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Breast Carcinoma | Metastatic Triple-Negative Breast Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Recurrent... and other conditionsUnited States
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingRecurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Malignant Ovarian Endometrioid Tumor | Ovarian High Grade Serous Adenocarcinoma | Platinum-Sensitive Ovarian Carcinoma | Fallopian Tube High Grade Serous Adenocarcinoma and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI); NanoPass Technologies LtdRecruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Fallopian Tube Carcinosarcoma | Primary Peritoneal Carcinosarcoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian... and other conditionsUnited States
-
Jonsson Comprehensive Cancer CenterTetraLogic Pharmaceuticals; California Institute for Regenerative Medicine... and other collaboratorsWithdrawnRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | High Grade Ovarian Serous Adenocarcinoma | High Grade Fallopian Tube Serous AdenocarcinomaUnited States
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Fallopian... and other conditionsUnited States, Puerto Rico
-
NRG OncologyNational Cancer Institute (NCI)RecruitingOvarian Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Fallopian Tube High Grade Serous Adenocarcinoma | Primary Peritoneal Endometrioid Adenocarcinoma | Ovarian High Grade Endometrioid Adenocarcinoma and other conditionsUnited States, Puerto Rico, Japan
Clinical Trials on Magnetic Resonance Imaging
-
Stanford UniversityTerminatedLaryngeal Neoplasms | Head and Neck Cancers | Larynx CancerUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Healthy SubjectUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)CompletedBreast CancerUnited States
-
Chinese University of Hong KongBeijing Tiantan HospitalRecruitingStroke | Brain Diseases | Ischemic Stroke | Stroke, Ischemic | Stroke, Acute | Stroke Hemorrhagic | Intracerebral Hemorrhage | Stroke (CVA) or TIAHong Kong
-
University of WarwickNorthern Care Alliance NHS Foundation Trust; University Hospitals Coventry... and other collaboratorsUnknown
-
Daniel M. SpielmanNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedMalignant Central Nervous System Neoplasm | Metastatic Malignant Neoplasm in the Central Nervous SystemUnited States
-
Abramson Cancer Center of the University of PennsylvaniaCompletedBrain TumorUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedThoracic Spine NeoplasmUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)Terminated